Rocket Pharmaceuticals Secures up to $150M Credit Facility from Hercules to Fund RP-A501 Pivotal Study

Rocket entered a credit facility with Hercules Capital providing up to $150M, with $35M received at closing. The financing supports execution of the pivotal Phase 2 study of RP-A501 for Danon disease and advancement of its cardiovascular gene therapy pipeline. Additional tranches are tied to clinical milestones and committee approval.

Thông tin chính

Nộp lúc: 21:15 6 thg 10, 2026
Sự kiện: Hợp tác / thỏa thuận cấp phép
Chiều hướng: Trung lập
Công ty: RCKTRocket Pharmaceuticals
Tài sản: RP-A501
Nguồn: SEC 8-K
Độ tin cậy: Có nguồn
Thời hạn sử dụng tiền mặt: Quý 3 năm 2028
Khoản rút ban đầu: 35 triệu đô la
Quy mô cơ sở: 150 triệu đô la

Trích đoạn nguồn

EX-99.1 4 ef20083350_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital CRANBURY, N.J. – October 6, 2026 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket’s financial position and provides access to additional capital to support execution of its pivotal Phase 2 study of RP-A501 for Danon disease and continued advancement of its broader cardiovascular pipeline. “Buildin

SEC 8-K